Tscan Therapeutics is trading 5.2% up at $0.77 today, appearing to follow a broader bid in the biotech sector and constructive overall market sentiment rather than a company-specific catalyst.
- There have been no fresh regulatory filings, press releases, or analyst actions reported for the company this week.
- Shares remain near the low end of their 52-week range, where light trading flows can drive relatively outsized percentage moves.